FDA approves Moderna's mRNA flu vaccine after initial refusal
The agency reversed course on reviewing Moderna's shot after public outcry, approving it for adults 50 and older based on trial data showing 26.6% greater efficacy than standard vaccines.
Conversation activity · last 4 days peak 1/hr
Summary, timeline and people extracted by Claude from 15 items across 3 sources · 9h ago. Quotes are verbatim.
The FDA approved Moderna's mRNA-based flu vaccine (mFlusiva) for adults aged 50 and older, marking the first mRNA flu shot authorization. The agency had initially refused to review the application but reversed that decision following public pressure. Clinical trials involving over 40,000 participants demonstrated the vaccine was 26.6% more effective than existing standard-dose flu vaccines.
- FDA approved Moderna's mRNA flu vaccine (mFlusiva) for adults 50+ after reversing its initial refusal to review the application following public pressure.
- Clinical trial data from 40,000+ participants demonstrated 26.6% greater efficacy than standard-dose flu vaccines, with approval granted despite RFK Jr.'s anti-mRNA vaccine activism.
- The vaccine is expected to be available at U.S. retailers in the coming weeks/year, while Health Canada continues its own review process.
- Canadian health experts highlighted the vaccine's particular benefits for older adults, immunocompromised individuals, and those with comorbidities.
How it unfolded
-
Analysis Discussion of political context
Gavin Yamey shared an NPR interview discussing the vaccine's efficacy and side effects, noting the political context surrounding RFK Jr.'s anti-vaccine activism and opposition to mRNA vaccine R&D.
-
Reaction Virologist celebrates approval on Bluesky
Angie Rasmussen highlighted the approval as positive news, noting the vaccine outperformed existing flu vaccine technology in clinical trials.
-
Report International health expert reaction
Canadian immunologists and infectious disease experts welcomed the FDA approval, with Dawn Bowdish noting mRNA vaccines are particularly protective for older people with comorbidities and immunocompromised individuals.
-
Reaction NPR reporting questioned on safety language
Social media commenter criticized NPR reporter Rob Stein for using the word 'seems' regarding safety when testing involved 40,000 participants, and questioned whether RFK Jr. was influencing NPR coverage.
-
Event FDA approves Moderna mRNA flu vaccine
The FDA approved Moderna's mRNA-based flu vaccine mFlusiva for adults aged 50 and older. The approval reversed an earlier FDA refusal to review the application.
-
Report Clinical trial efficacy results disclosed
FDA approval was based on late-stage trial data from over 40,000 adults aged 50 and older, showing the vaccine was 26.6% more effective than existing standard-dose flu vaccines.
What people are saying verbatim
“FDA approved the Moderna mRNA flu vaccine, which is great news for everyone! In clinical trials it outperformed existing flu vaccine technology so well that not even Vinay Prasad could cancel it.”
angierasmussen.bsky.social · Bluesky · Aug 5
“Tested on 40,000 people, FDA is poised to approve it, and it....'seems' safe? I think 40K is a good number to say 'is' safe.”
chirojoe.bsky.social · Bluesky · Aug 4
“The reason I think this is exceptionally good news is because the mRNA vaccines seem to be very protective of people who are older, with comorbidities, and people who are immunocompromised.”
Dawn Bowdish, Immunologist, McMaster University · CBC News · Aug 5
“Something that is more efficacious is obviously going to decrease not only the toll on people's health, but also the toll on hospitals and health-care clinics across the country and certainly across the globe, which I think is a big consideration.”
Jason Kindrachuk, Associate professor, University of Manitoba · CBC News · Aug 5
“The agency had initially refused to even review the application but reversed course after a public outcry.”
Christina Jewett, NYT reporter · New York Times · Aug 5
Voices from the web unedited
-
FDA approved the Moderna mRNA flu vaccine, which is great news for everyone! In clinical trials it outperformed existing flu vaccine technology so well that not even Vinay Prasad could cancel it. I talked to Scott Tong at @npr.org @hereandnow.bsky.social about it
-
Terrific @npr.org interview w/ @angierasmussen.bsky.social on Moderna’s mRNA flu vaccine virologist @angierasmussen.bsky.social She discusses efficacy, side effects, and of course the politics—given RFK Jr’s extreme anti-vaxx activism & hatred of mRNA vaccine R&D